Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial

Arun Sedhain 1*, Rajani Hada 2, Rajendra K. Agrawal 2, Gandhi R. Bhattarai 3 and Anil Baral 2

Abstract

Background: The management of proliferative lupus nephritis (LN) comprises timely and coordinated immunosuppressive therapy. This study aimed to evaluate and compare the effectiveness and safety profile of low dose mycophenolate mofetil (MMF) and cyclophosphamide (CYC) in induction therapy of LN in Nepalese population.

Methods: We conducted a prospective, open-label, randomized trial over a period of one and half years. Forty-nine patients with class III to V lupus nephritis were enrolled, out of which 42 patients (21 in each group) could complete the study. CYC was given intravenously as a monthly pulse and MMF was administered orally in the tablet form in the maximum daily dose of 1.5 g in two divided doses.

Results: The mean age of the patients was 25.43 ± 10.17 years with female to male ratio of 7.3:1. Mean baseline serum creatinine was 1.58 ± 1.38 mg/dL and eGFR was 62.38 ± 26.76 ml/min/1.73m². Mean 24-h urinary protein was 4.35 ± 3.71 g per 1.73 m² body surface area. At 6 months, serum creatinine (mg/dL) decreased from 1.73 to 0.96 in CYC and from 1.24 to 0.91 in the MMF group with improvement in eGFR (ml/min/1.73 m²) from 60.33 to 88.52 in CYC and from 64.42 to 89.09 in MMF group. Twenty-four-hour urinary protein (gm/1.73m²) reduced from 4.47 to 0.94 in CYC and from 4.5 to 0.62 in the MMF group. Primary end point was achieved in higher percentage of patients with MMF than CYC (28.6% vs. 19%) while equal proportion of patients (67% in each group) achieved secondary end point in both groups. Number of non-responders was higher in CYC group than in the MMF group (14.3% vs. 4.8%). There was no difference in the rate of achievement of secondary end point in both CYC and MMF groups (3.16 vs. 3.05 months). The occurrence of adverse events was higher in the CYC group (14.3%) as compared to MMF group (6% vs. 15 events).

Conclusion: Present study has concluded that MMF, used in relatively lower dose, is equally effective in inducing remission with reduction of proteinuria and improvement of kidney function with lesser adverse events than CYC in the induction therapy of proliferative lupus nephritis.

Trial registration: Retrospectively registered to ClinicalTrials.gov PRS. NCT03200002 (Registered date: June 28, 2017).

Keywords: Lupus nephritis, Induction therapy, Cyclophosphamide, Mycophenolate mofetil
Background
Lupus nephritis (LN), a common presentation occurring in approximately 35 to 50% of patients with systemic lupus erythematosus (SLE) [1], is characterized by an extremely heterogeneous phenomenon [2]. Management of lupus nephritis requires a timely and coordinated use of immunosuppressive therapy, which consists of induction and maintenance phases. One of the goals of management of LN is to achieve the best possible clinical efficacy with renal remission and minimal toxic effects of the immunosuppressive agents.

Effectiveness of cyclophosphamide (CYC) over corticosteroid alone in the management of LN was established in the National Institutes of Health (NIH) trials [3, 4]. The Euro–lupus nephritis trial (ELNT) demonstrated a comparable efficacy and safety profile of low-dose CYC to the high-dose NIH regimen [5]. Since then, CYC remains a reliable and effective treatment for inducing remission in lupus nephritis [6]. However, its use is associated with significant dose-dependent short- and long-term toxicity [7]. Mycophenolate mofetil (MMF), a selective lymphocyte antiproliferative agent, has emerged as one of the first-choice regimens for inducing a remission in severe active proliferative LN [8–11]. A relatively large international multicenter trial by Aspreva lupus management study (ALMS) group established the equal efficacy with relatively identical adverse effect profiles of MMF in comparison to CYC [12]. However, the dose of MMF used in this study was relatively higher and it is not clear whether low-dose MMF or CYC is superior, because these have not been compared in a head-to-head trial. The present study was aimed at comparing the efficacy and safety of low dose MMF with CYC in Nepalese LN patients.

Methods
Study design and subjects
This was a prospective, open-label, randomized control trial conducted in the Department of Nephrology at National Academy of Medical Sciences (NAMS), Bir Hospital, Kathmandu, Nepal, between January 2014 to June 2015. The procedures followed were in accordance with the ethical standards of the responsible committees on human experimentation (institutional and national) and with the Declaration of Helsinki Principles 1975, as revised in 2000. The study was carried out after getting approval from the institutional review board (IRB) of NAMS and has been registered to ClinicalTrials.gov PRS. (NCT03200002) with registration date of June 28, 2017. Enrolled subjects were made aware of the investigational nature of the study and informed written consent was obtained from the adult patient or the parent of the children below 18 years of age, before enrolling the participants.

A total of 53 patients, aged 13 years and older, diagnosed to have SLE as per American College of Rheumatology (ACR) criteria [13], and biopsy-proven class III, IV, V, III + V, or IV + V LN based on the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification [14] were screened. Patients with previous history of treatment and relapse of LN, who were receiving continuous dialysis for more than two weeks prior to randomization, who had concurrent infection or illness at the time of enrollment, female patients who were pregnant and breastfeeding and those who refused to give consent were excluded from the study. Forty-nine patients met the entry criteria and were enrolled in the study comprising of 25 and 24 patients in the MMF and CYC group respectively. The first patient was selected by a coin-toss for either MMF or CYC group and all subsequent patients were randomized alternatively in 1:1 ratio. Forty-two patients comprising 21 in each group could complete the study till the end of 6 months and were included for analysis. Those who didn’t return for follow-up or had an interruption of more than 10 days during the course of treatment were excluded from the analysis (Fig. 1).

Detailed history was taken; physical examination was done and recorded in the preformed pro-forma of the study. Investigations at baseline included complete blood count (CBC), renal function test (RFT), blood sugar level, serum calcium and phosphate, serum total protein, albumin, and antinuclear antibody (ANA), routine and microscopic examination of urine, 24-h urinary total protein excretion, fasting lipid profile, ultrasonography (USG) examination of the abdomen and pelvis and chest X-ray. Serum creatinine was tested by CRE2 method, which employs a modification of the kinetic Jaffe reaction with the use of SIEMENS fully automated Dimension* vista* clinical chemistry system [15]. Estimated glomerular
filtration rate (eGFR) was calculated by 4-variable Modification of Diet in Renal Disease (MDRD) Study equation [16]. The clinical details including the laboratory investigation findings was recorded as baseline data.

Study treatment and drug dosing
Patients in the MMF group were administered tablet mycophenolate mofetil at a starting dose of 750 mg twice daily if the weight was more than 50 kg. For those below 50 kg of body weight, the dose was started at 500 mg twice daily and increased to 750 mg twice daily after 30 days. The clinical response was monitored in terms of reduction in serum creatinine and 24-h proteinuria.

Those in the CYC group received the drug intravenously in the dose of 0.5 to 1 g per m² of body surface area. Pulse CYC was administered every month for a total of six infusions. CYC, which is available in the powder form in a vial, was first dissolved in 20 ml of normal saline and then mixed in 100 ml of normal saline. The solution was infused over a period of one hour. At any point during the course of treatment, CYC was not given to those patients who had total leucocyte counts (TLC) less than 2500/mm³. Those patients were re-evaluated after one week and intravenous pulse CYC was reinstituted if the TLC increased to more than 2500/mm³.

Patients were monitored monthly and the clinical details were recorded. Any adverse events in between were noted and detailed physical evaluation was done and major baseline investigations except USG abdomen, chest X-ray, serum ANA and anti-double-stranded deoxyribonuclease (anti dsDNA) were repeated. If a patient had interruption of medication for more than a 10 days period due to any reason, the patient was withdrawn from the study.

All patients in both cohorts received concomitant corticosteroid therapy with oral prednisolone and hydroxychloroquine. Angiotensin receptor inhibitors (ACEi)/angiotensin receptor blockers (ARBs) were given to all patients if the blood pressure remained above or equal to 120 mmHg of systolic blood pressure and 80 mmHg of diastolic blood pressure. Oral prednisolone was given at an initial dose of 1 mg/kg with a maximum dose of 60 mg/day. The starting dose of prednisolone was continued for initial one month. Then, the dose of oral prednisolone was tapered at the rate of 10 mg every 2 weeks and was maintained at the baseline dose of 5 to 7.5 mg per day then after.

Study end points
The primary outcome measure was 'treatment response' defined as a decrease in proteinuria - reduction of 24-h urinary total protein (UTP) to less than 3.5 g in patients with baseline nephrotic range proteinuria (UTP of ≥3.5 g) or decrease in the UTP by > 50% in patients with sub-nephrotic proteinuria (UTP < 3.5 g); or stabilization (+/- 25%) or reduction of serum creatinine and rise of eGFR from the baseline value. Secondary end point was return of serum creatinine to previous baseline, plus a decline in the 24-h UTP to less than 500 mg.

Statistical analysis
Patient characteristics were summarized using mean and frequency distributions. Data for continuous variables were expressed as mean ± standard deviation. T-test was used to compare the mean difference of each group. Chi-square test or Fisher’s Exact test, suitable for 2×2 contingency table were used for test of independence. Analysis of Variation (ANOVA) tests were done to test the differences of continuous variables across multiple groups. Descriptive and inferential statistical analysis were done by using SAS University Studio package.

Results
A total of 42 patients could complete the 6 months of study period. Details of patient recruitment is summarized in Fig. 1.

The patient age ranged from 13 to 68 years (mean 25.93 ± 10.21). There were 37 females and 5 males with female to male ratio of 7.4:1. All included baseline characteristics were comparable between two groups (Table 1). Baseline mean hemoglobin of the patients was 10.33 ± 1.95 g/dL. Mean serum creatinine was 1.47 ± 1.05 mg/dL, which was, though statistically not significant, was higher in CYC group than in MMF group (1.73 ± 1.72 vs 1.22 ± 0.53) with eGFR of 60.33 ± 28.70 ml/min and 64.42 ± 25.21 ml/min in CYC and MMF groups respectively. Although statistically insignificant, baseline disease severity indices as per SLEDAI (Systemic lupus erythematosus disease activity index) were higher in CYC group than in MMF group (Table 1).

According to systemic lupus international collaboration clinic (SLICC) classification criteria for SLE [17], 11 (26.2%) patients met 4 to 6 criteria, 28 (66.6%) met 7 to 9 criteria and 3 (7.14%) met ≥10 criteria. Nineteen patients in each group of CYC and MMF received angiotensin receptor blocker (ARB) and rest 2 in each group received angiotensin converting enzyme inhibitor (ACEi).

Mean activity index (AI) at baseline was 8.09 ± 4.55 in CYC and 8.23 ± 3.22 in MMF group whereas chronicity index (CI) was 1.76 ± 1.72 and 2.61 ± 1.68 in CYC and MMF groups respectively. Crescents were present in 19.04% in CYC and 9.52% in MMF group and these patients who had crescents on kidney biopsy received steroid pulse therapy at the beginning of the treatment.
Study outcome

Achievement of primary and secondary end points in both of the treatment groups were assessed at the end of 3 and 6 months. The rates of treatment response and complete renal remission at these time points are summarized in Table 2. The average dose of the steroids used by the patients in CYC groups at the end of 3 months and 6 months was 32.74 and 12.54 mg/day and in the MMF group this dose was 31.82 and 11.46 mg/day respectively.

At the end of 3 months eGFR improved to 81.95±41.28 ml/min/1.73m² in CYC and 76.71±28.27 ml/min/1.73 m² in MMF group. At the end of 6 months, improvement of eGFR was 88.52±35.17 and 89.09±34.34 ml/min/1.73m² in CYC and MMF groups respectively. Disease activity as measured by SLEDAI score also significantly improved with the treatment. SLEDAI score decreased to 6.5±2.1 in CYC and 5.6±2.1 in MMF group at the end of 3 months and 3.23±1.32 in CYC and 2.34±1.79 at the end of 6 months respectively.

At the end of 6 months, achievement of primary end point was slightly higher in MMF group than the CYC group (28.6% versus 19%), whereas achievement of secondary end point was equal in both groups (66.7% each). Three patients (14.3%) in the CYC group and 1 (4.8%) in the MMF group did not achieve response at the end of study period (6 months).

Though statistically non-significant, the average time to achieve both primary (3.21 vs. 3.5 months; \( p = 0.610 \)) and secondary end points (3.05 versus 3.16 months; \( p = 0.817 \)) was relatively shorter in MMF group than in the CYC group.

The treatment response rate at the end of 6 months in ISN/RPS class III and combined classes III and V was better than in classes IV and combined classes of IV and V (41.7% versus 16.7%). Secondary end point, which was achieved in 14 patients in each group, is shown in Table 3.

The changes in important renal parameters in 3 and 6 months of treatment in both groups is shown in Fig. 2.

Baseline characteristics that predicted better achievement of complete remission (secondary end point in our study) in comparison to partial remission (primary end point) were younger age of the patients (24 versus 34 years; \( p = 0.009 \)), lesser degree of 24-h proteinuria (3.5 vs 7.45 g/1.73m²; \( p = 0.010 \)) and lesser activity index on renal histology (1.68 vs. 3.7; \( p = 0.001 \)).

Adverse events

More than three quarters of the patients in CYC group experienced alopecia and nausea/vomiting which was absent in MMF group. Among other common adverse events, headache (38.09% vs. 19.04%) and backache (28.57% vs 19.04%) were observed by more patients in CYC group than the MMF group albeit with no statistical difference. Infection related side effects like urinary tract infection, herpes zoster and chest infection were more common in CYC group than MMF group (47.61% vs. 33.33%) (Table 4). Two patients required hospital admission for the treatment of chest infection. None of

### Table 1 Baseline characteristics of the study population

| Variables                     | CYC (n = 21) | MMF (n = 21) | P-value |
|-------------------------------|-------------|-------------|--------|
| Age (years)                   | 24.67 ± 11.66 | 27.24 ± 9.34 | 0.435  |
| Gender, n (%)                 |             |             |        |
| Female                        | 19 (90.5)   | 18 (85.7)   | 1.000  |
| Male                          | 2 (9.5)     | 3 (14.3)    |        |
| Body Mass Index (kg/m²)       | 19.64 ± 3.00 | 21.00 ± 3.08 | 0.154  |
| BSA (m²)                      | 1.48 ± 0.14 | 1.44 ± 1.38 | 0.404  |
| SLEDAI Score                  | 16.21 ± 4.32 | 15.92 ± 3.45 | 0.653  |
| SLICC Criteria                | 11.23 ± 2.34 | 10.56 ± 4.78 | 0.562  |
| eGFR Range (ml/min/1.73m²), n (%) |          |             |        |
| ≥ 90                          | 3 (14.3)    | 6 (28.6)    | 0.381  |
| 60–89                         | 10 (47.6)   | 6 (28.6)    |        |
| ≤ 59                          | 8 (38.1)    | 9 (42.9)    |        |
| Renal biopsy class, n (%)     |             |             |        |
| Class III/III + V             | 5 (23.8)    | 4 (19.0)    | 0.143  |
| Class IV/IV + V               | 16 (76.2)   | 13 (62)     |        |
| Class V                       | 0           | 0           |        |
| Activity index (Al)           | 8.09 ± 4.55 | 8.23 ± 3.22 | 2.342  |
| Chronicity index (CI)         | 1.76 ± 1.72 | 2.61 ± 1.68 | 1.453  |
| Crescents, n (%)              | 4 (19.04)   | 2 (9.52)    | 0.092  |
| Serum urea (mg/dL)            | 62.86 ± 56.62 | 46.05 ± 38.05 | 0.266 |
| Serum creatinine (mg/dL)      | 1.73 ± 1.72 | 1.24 ± 0.53 | 0.223  |
| Positive anti-dsDNA, n (%)    | 17 (81.0)   | 19 (90.5)   | 0.663  |
| Serum albumin (gm/dL)         | 2.75 ± 0.65 | 2.98 ± 0.67 | 0.266  |
| Urinary 24-h protein excretion (gm) | 3.32 ± 3.53 | 3.30 ± 2.42 | 0.993  |

SLEDAI Systemic Lupus Erythematosus Disease Activity Index, SLICC Systemic Lupus International Collaborative Clinic

### Table 2 Outcomes of treatment in two treatment groups

| Efficacy measurement | End of 3 months | End of 6 months |
|----------------------|-----------------|-----------------|
|                      | CYC (47.6%)     | MMF (33.3%)     | p-value |
| Primary End point    | 10              | 7               | 0.454   |
| Secondary end point  | 6 (28.6%)       | 10 (47.6%)      |        |
| No Response          | 5 (23.8%)       | 4 (19.0%)       |        |
|                      |                 |                 |         |
|                      | CYC (19.0%)     | MMF (28.6%)     | p-value |
|                      | 4               | 6               | 0.572   |
|                      | 14 (66.7%)      | 14 (66.7%)      |        |
|                      | 3 (14.3%)       | 1 (4.8%)        |        |
the patients died during the course of the treatment and not a single patient showed severe adverse events requiring discontinuation of treatment in both groups.

**Discussion**

Newer therapeutic approaches to achieve best possible efficacy with lesser toxicity in the management of LN are being explored [18, 19]. Randomized, controlled trials at the National Institutes of Health (NIH) in patients with severe, proliferative LN established the better efficacy of CYC over use of corticosteroid alone but the treated subjects were not free of major adverse reactions of the drug [3]. Further studies were carried out to establish the reduced toxic profiles of CYC by using lower dose without compromising the efficacy. The Euro-lupus nephritis trial (ELNT) had compared six fortnightly injections of CYC at a fixed dose of 500 mg with high-dose monthly injections [5]. Follow-up for up to 10 years showed that there were no differences in the outcomes parameters or the side effects between high- and low-dose intravenous CYC [20].

In other studies, MMF was tested as an alternative to CYC as initial therapy of proliferative LN and it was found to be non-inferior to CYC [12, 21, 22]. Aspreva Lupus Management Study (ALMS) was a non-inferiority trial, which established almost equal results of MMF when compared with CYC in the treatment of proliferative LN [12]. In a meta-analysis of 45 trials that involved 2846 patients, there were no significant differences between CYC and MMF based induction therapy with respect to mortality, incidence of end stage renal disease (ESRD) and relapse during induction. MMF produced a numerically higher rate of complete responses (19.5 versus 13.8%), although this was not statistically significant. Major infections like pneumonia were also similar with both drugs [23]. However, the standard dose of MMF with the target dose of 3 g/d was used in all those studies. To date there have been no studies directly comparing the low-dose MMF with intravenous CYC pulse regimen.

In this randomized trial, the efficacy and safety of low dose MMF, with target daily dose of 1.5 g/d, was compared with intravenous pulse CYC in the induction phase of therapy of LN. Treatment response and complete remission rates, as well as adverse event rates were comparable in the two groups. Comparison of efficacy measurements at the end of study period between two groups has shown better achievement of primary end point in MMF than CYC groups (28.6% vs. 19%) though it was not statistically significant. This result is similar to ALMS study with achievement of primary end point in MMF and CYC (63.7% vs. 57.1%; P = 0.32) [12] and reported by Ginzler et al. (56.2% vs 53.0%; P = 0.51) [24]. However, achievement of primary end point in ALMS was much higher than in our study.

Secondary end point was achieved in equal proportion of patients in both groups (67% in each). Despite relatively worse renal function in CYC than MMF groups (serum creatinine: 1.73 mg/dL vs 1.24 mg/dL) at presentation, the achievement of secondary end point did not differ in both groups.

In our study, despite a lower received MMF dose higher response rate was achieved. The composite renal remission (combination of secondary and primary end point) was better in MMF group than CYC group (85.71% vs. 76.19%) though statistically insignificant. In ALMS report, complete remission was calculated in terms of three variables- serum creatinine, 24-h proteinuria and active urinary sediments. MMF showed better response than CYC by serum creatinine (70.3% vs 67.6%) and urinary sediments (31.4% vs. 23.8%) and lesser response by 24-h proteinuria (23.8% vs. 27%) criteria. Better response rate was seen in MMF group even on comparison of all three criteria collectively with complete remission in 8.6% in MMF and 8.1% in CYC group and partial remission 56 and 53% in these groups respectively [12]. Our study showed better composite outcome at the end of study compared to ALMS study probably due to not including urinary sediment criteria and relatively small sample size. Achievement of complete remission in our study is also better than the findings reported by Rathi et al. in their study done in Asian population, which compared MMF with low dose CYC. At the end of 24 weeks they found to have 74% of renal response in both the groups, whereas complete renal remission was achieved in 54% in the MMF group and 50% in the CYC group [25].

The composite renal response, as calculated by combination of primary and secondary end points, was slightly higher in classes III + V than classes IV + V (91.66% vs. 90.0%). Though, the explanation is not fully explainable. This result is contrary to the findings of Lupus Nephritis Collaborative Study Group, which had predicted higher likelihood of complete remission and a lower risk of renal failure in class IV LN than class III LN [26].

The occurrence of adverse events was five times more in the CYC than in MMF group (75 events vs. 15 events) in this study. Though the infection related adverse events were comparable in both groups (10 in CYC
versus 7 in MMF), other milder symptoms like alopecia, nausea/vomiting and headache were more commonly observed in the CYC group (46 events vs 8 events). These findings were similar to other studies, in which MMF has been reported to be well tolerated than CYC [12, 27]. In one study pyogenic infections were found to be associated more with CYC and diarrhea more common with MMF [28]. In a recent randomized control trial, which compared MMF with low dose CYC in Indian population, although not significant, more adverse events were noted with MMF with similar infection related episodes in both groups [25]. With higher proportion of infection related to CYC use, our suggestion would be to take utmost care with close vigilance to the infection related adverse events while using CYC in the management of LN especially in this part of the world, where higher rates of various infections are prevalent.

**Strengths and limitations**

This was the first study to compare lower than the conventional dose of MMF with CYC in Nepalese population. This was a single-center study. Thus, the results need validation in a large multicenter study. Our study also had a short follow-up that limits the durability of response over the long term. The study was not blinded, and this might have led to biases in recruitment of subjects or analysis of results. Larger multicenter studies with a longer follow-up are required to extrapolate these results to lupus populations in other parts of the world.

**Conclusions**

Present study has concluded that low dose of MMF is as equally effective as intravenous CYC in inducing remission with reduction of proteinuria and improvement of kidney function with better safety profile in proliferative lupus nephritis in 6 months therapy in Nepalese population.
Abbreviations
ACEI: Angiotensin receptor inhibitors; ACR: American college of rheumatology; ALMS: Aspreva lupus management study; ANA: Antinuclear antibody; ANOVA: Analysis of Variance; ARB: Angiotensin receptor blocker; CBC: Complete blood count; CYP: Cyclophosphamide; eGFR: Estimated glomerular filtration rate; ELNT: Euro lupus nephritis trial; IRB: Institutional review board; ISN/RPS: International Society of Nephrology/Renal Pathology Society; LN: Lupus nephritis; MDRD: Modification of Diet in Renal Disease; MMF: Mycophenolate mofetil; NAMS: National Academy of Medical Sciences; NIH: National Institutes of Health; RFT: Renal function test; SLE: Systemic lupus erythematosus; SLICC: Systemic lupus international collaboration clinic; USCG: Ultrasoundography; UTP: 24-h urinary protein.

Acknowledgements
We would like to thank the nurses of the department of Nephrology at Bir Hospital for their kind co-operation to complete the study successfully. We are thankful to the patients with lupus nephritis for their participation in the study.

Availability of data and materials
The datasets generated and/or analyzed during the current study are available on figshare repository. The link is: https://figshare.com/articles/MASTER_Chart_May_31_2018_xlsx/6396050.

Authors’ contributions
AS– Conceived the study and its design, collected data, prepared the first manuscript, Periodic coordination. RH– Conceived the study, critically reviewed and revised the manuscript. RKA– Conceived the study, critically reviewed and revised the manuscript. GRB– Did statistical analysis of the data, critically reviewed and revised the manuscript. RB– Collected data and critically reviewed and revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Ethical approval was obtained from the Institutional Review Board of National Academy of Medical Sciences (NAMS), Kathmandu, Nepal. Patients gave informed written consent to participate in the study. Written informed consent was also obtained from the parents of the participants below 18 years of age.

Consent for publication
Not applicable.

Competing interests
AS is employed by Chitwan Medical College and does not have financial benefits in participating in the study.
RH, RKA and AB are employed by the Government of Nepal and currently posted at National Academy of Medical Sciences and have not received any financial benefits for getting involved in the study.
GRB is employed by UnitedHealth Group and also owns company stocks. No financial benefits for getting involved in the study.

Ethics approval and consent to participate
Not applicable.

References
1. Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010;21:2028–35.
2. D’Cruz DP, Khamashia MA, Hughes GR. Systemic lupus erythematosus. Lancet. 2007;369:587–96.
3. Austin IIIHA, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314:614–9.
4. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Mycophenolate mofetil and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125:549–57.
5. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrod Ed Ede R, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121–31.
6. Boumpas DT, Austin HA 3rd, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992;340:741–45.
7. Ponticelli C. Treatment of lupus nephritis: the advantages of a flexible approach. Nephrol Dial Transplant. 1997;12:2057–9.
8. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou nephrology study group. N Engl J Med. 2000;343:1156–62.
9. Ye Z, Tan YH, Hong XP, et al. MMF vs CTX in the treatment of severe SLE patients. Lupus. 2001;10(Suppl 1):S99, 274.
10. Ong LM, Hooi LS, Lim TO, Goh BI, Ahmad G, Ghazalli R, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrol, (Carlton). 2005;10:504–10.
11. Lee Y, Woo JH, Choi S, Ji J, Song G. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus. 2010;19:703–10.
12. Appel GB, Contreras G, Dooley MA, Ginzier EM, Isenberg D, Jayne D, Li LS, Mysler E, Sanchez-Guerrero J, Solomons N, Wofsy D. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1013–22.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
14. Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241–50.
15. Peake M, Whiting M. Measurement of serum creatinine – current status and future goals. Clin Biochem Rev. 2006;27(4):173–84.
16. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–54.
17. Petri M, Orbai AM, Alarcón GS, Gordon C, Meinl JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86. https://doi.org/10.1002/art.34473.
18. Bhat P, Radhakrishnan J. B lymphocytes and lupus nephritis: new insights into pathogenesis and targeted therapies. Kidney Int. 2008;73:261–8.
19. Bagavant H, Kalantarina K, Scindia Y, et al. Novel therapeutic approaches to lupus glomerulonephritis: translating animal models to clinical practice. Am J Kidney Dis. 2011;57:498–507.
20. Houssiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the euro-lupus nephritis trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2009;69:691–4.
21. Walsh M, James M, Jayne D, Tonelli M, Mannis BJ, Hemmelgarn BR. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2007;2:2068–75.
22. Zhu B, Chen N, Lin Y, Ren H, Zhang W, Wang W, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant. 2007;22:1933–42.
23. Henderson LK, Masson P, Craig JC, Roberts MA, Flanc RS, Webster AC. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2013;61:74.
24. Ginzier EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219–28.
25. Rathi M, Goyal A, Ajay Jaryal A, Sharma A, Gupta PK, Ramachandran R, et al. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int. 2016; 89:235–42. https://doi.org/10.1038/ki.2015.318

26. Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Collaborative study group. Significance of histologic patterns of glomerular injury upon the long-term prognosis in severe lupus glomerulonephritis. Kidney Int. 2000;59:2156–63.

27. Kamanamool N, McEvoy M, Attia J, Ingsathit A, Ngamjanyaporn P, Thakkinstian A. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore). 2010;89(4):227–35.

28. Alamoudi OSB, Attar SM. Pulmonary manifestations in systemic lupus erythematosus: association with disease activity. Respirology. 2015;20:474–80. https://doi.org/10.1111/resp.12473.